SINGAPORE - A newly approved first-of-its-kind biologic drug may bring hope to patients who are having a hard time bringing their moderate to severe atopic eczema under control.

Some patients at both public and private institutions, including adolescents, have been treated with the newly available Dupilumab, sold under the brand name Dupixent, which has been shown to be relatively safe and effective in international trials that included Singapore. The Health Sciences Authority approved its use in adult patients about two months ago.